Amgen's Long-Acting Obesity Drug

Jim speaks with Amgen CEO Robert Bradway about once-monthly GOP-1, long-term weight-loss maintenance and rare disease growth.

Play episode from 18:50

Transcript

The AI-powered Podcast Player

Save insights by tapping your headphones, chat with episodes, discover the best highlights - and more!